IL6 and lung carcinoma: Increased Sp1 and the nuclear factor for IL-6 expression (NF-IL6) CCAAT/enhancer binding protein (C/EBP)-dependent activation may lead to PPARγ ligand-induced elevation of p21 gene expression, unveiling a process for p21 gene regulation in lung carcinoma that could be a potential lung cancer therapy [171].